Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects

In 2011, the Vysis Break Apart ALK fluorescence in situ hybridization (FISH) assay was approved by the United States Food and Drug Administration as a companion diagnostic for detecting ALK rearrangement in lung cancer patients who may benefit from treatment of tyrosine kinase inhibitor therapy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zhenya, Wang, Lu, Tang, Guilin, Medeiros, L. Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720438/
https://www.ncbi.nlm.nih.gov/pubmed/31412611
http://dx.doi.org/10.3390/ijms20163939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720438/
https://www.ncbi.nlm.nih.gov/pubmed/31412611
http://dx.doi.org/10.3390/ijms20163939

Ejemplares similares